Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ.

Gastroenterology. 2003 Jun;124(7):1774-85.

PMID:
12806611
2.

Infliximab induced T lymphocyte apoptosis in Crohn's disease.

van den Brande J, Hommes DW, Peppelenbosch MP.

J Rheumatol Suppl. 2005 Mar;74:26-30. Review.

PMID:
15742461
3.

Diverse effects of infliximab and etanercept on T lymphocytes.

Sieper J, Van Den Brande J.

Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):23-7. Review.

PMID:
15852251
4.

Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease.

Kirman I, Whelan RL, Nielsen OH.

Eur J Gastroenterol Hepatol. 2004 Jul;16(7):639-41. Review.

PMID:
15201575
5.

Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease.

Shetty A, Forbes A.

Am J Pharmacogenomics. 2002;2(4):215-21. Review.

PMID:
12421092
6.

Anti-TNF agents in Crohn's disease.

Van Assche G, Rutgeerts P.

Expert Opin Investig Drugs. 2000 Jan;9(1):103-11. Review.

PMID:
11060664
7.

Anti-TNF therapy in Crohn's disease.

Ghosh S.

Novartis Found Symp. 2004;263:193-205; discussion 205-18. Review.

PMID:
15669643
8.

Treating Crohn's disease by inducing T lymphocyte apoptosis.

Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ.

Ann N Y Acad Sci. 2002 Nov;973:166-80. Review.

PMID:
12485856
9.

Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.

Korzenik JR.

Gastroenterol Clin North Am. 2004 Jun;33(2):285-301, ix. Review.

PMID:
15177539
10.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

11.

Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.

Ganesan S, Travis SP, Ahmad T, Jazrawi R.

Curr Opin Investig Drugs. 2002 Sep;3(9):1301-6. Review.

PMID:
12498004
12.

Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.

LaDuca JR, Gaspari AA.

Dermatol Clin. 2001 Oct;19(4):617-35. Review.

PMID:
11705350
13.

Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.

Akobeng AK, Zachos M.

Cochrane Database Syst Rev. 2004;(1):CD003574. Review.

PMID:
14974022
14.

Why do anti-tumor necrosis factor antibodies work in Crohn's disease?

Sands BE.

Rev Gastroenterol Disord. 2004;4 Suppl 3:S10-7. Review.

PMID:
15580148
15.

Biological therapies for inflammatory bowel disease: research drives clinics.

Danese S, Semeraro S, Armuzzi A, Papa A, Gasbarrini A.

Mini Rev Med Chem. 2006 Jul;6(7):771-84. Review.

PMID:
16842127
16.

Transcending conventional therapies: the role of biologic and other novel therapies.

Sandborn WJ.

Inflamm Bowel Dis. 2001 May;7 Suppl 1:S9-16. Review.

PMID:
11380043
17.
18.

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.

Carroll MB, Bond MI.

Semin Arthritis Rheum. 2008 Dec;38(3):208-17. doi: 10.1016/j.semarthrit.2007.10.011. Epub 2008 Jan 25. Review.

PMID:
18221983
19.

Strategies for targeting tumour necrosis factor in IBD.

Sandborn WJ.

Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):105-17. Review.

PMID:
12617886
20.

Patient outcomes after anti TNF-alpha drugs for Crohn's disease.

Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):163-75. doi: 10.1586/erp.10.13. Review.

PMID:
20384563

Supplemental Content

Support Center